论文部分内容阅读
高脂血症(HC)主要指血中总胆固醇(TC)和(或)低密度脂蛋白胆固醇(LDL-C)和(或)甘油三酯(TG)增高。高脂血症在动脉粥样硬化(AS)的发生发展及其引起心血管事件(CVE)中起非常重要的作用,是近年来AS和冠心病(CHD)防治研究的热点。其中羟甲基戊二酸单酰辅酶A(HMGC-COA)还原酶抑制剂即他汀类调脂药作用的研究取得了很大的进展。现综述如下。 1 调脂治疗的意义许多研究表明他汀类调脂药对AS及CHD一级预防、二级预防中具有重要的意义。1994年4S试验首次证明降低LDL-C可降低CHD的CVE和死亡率。从CHD一级预防干预研究中,美国弗明汉研究显示,TC下降1％,CVE减少2％。1995～1998年公布的CHD一级预防试验(AF/FERCAPS)共有6000多例HC病人参加,分别服用普伐他汀7年和洛伐他汀5.7年。
Hyperlipidemia (HC) mainly refers to the blood total cholesterol (TC) and (or) low density lipoprotein cholesterol (LDL-C) and (or) triglyceride (TG) increased. Hyperlipidemia plays a very important role in the development of atherosclerosis (AS) and its cause of cardiovascular events (CVE). It is a hot topic in prevention and treatment of AS and coronary heart disease (CHD) in recent years. In which hydroxymethyl glutaryl coenzyme A (HMGC-COA) reductase inhibitors that the effect of statin lipid-lowering drugs made great progress. Are summarized below. A significance of lipid-lowering therapy Many studies have shown that statin lipid-lowering drugs on AS and primary prevention of CHD, secondary prevention of great significance. 1994 4S test for the first time to prove that lowering LDL-C can reduce CHD CVE and mortality. From the CHD primary prevention intervention study, the United States Framingham study showed that TC decreased 1%, CVE decreased 2%. Over 6,000 HC patients participated in the CHD Primary Prevention Trial (AF / FERCAPS) from 1995 to 1998, taking pravastatin for 7 years and lovastatin for 5.7 years respectively.